Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines

US7622123B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Mario H. Skiadopoulos · Potomac, US
• Peter L. Collins · Kensington, US
• Brian R. Murphy · Bethesda, US
• Alexander C. Schmidt · Washington, US

Key dates

• Filing date: Nov 4, 2004
• Grant date: Nov 24, 2009
• Expiry date: Nov 4, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18661
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.